JW Lifescience Corporation (KRX:234080)
South Korea · Delayed Price · Currency is KRW 12,600
-310 (-2.40%)
Last updated: Apr 2, 2026, 2:33 PM KST
JW Lifescience Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 257,829 | 222,478 | 206,860 | 188,931 | 169,817 |
Other Revenue | - | - | - | -0 | -0 |
| 257,829 | 222,478 | 206,860 | 188,931 | 169,817 | |
Revenue Growth (YoY) | 15.89% | 7.55% | 9.49% | 11.26% | -7.47% |
Cost of Revenue | 185,577 | 165,010 | 154,507 | 140,972 | 120,788 |
Gross Profit | 72,252 | 57,468 | 52,353 | 47,959 | 49,029 |
Selling, General & Admin | 30,542 | 16,518 | 15,100 | 13,358 | 12,908 |
Research & Development | 5,550 | 4,030 | 5,161 | 5,737 | 6,242 |
Amortization of Goodwill & Intangibles | 1,418 | 278.99 | 403.54 | 744.89 | 493.83 |
Other Operating Expenses | 374.82 | 262.41 | 161.56 | 159.04 | 162.39 |
Operating Expenses | 39,008 | 21,610 | 21,491 | 20,870 | 20,612 |
Operating Income | 33,244 | 35,858 | 30,862 | 27,089 | 28,417 |
Interest Expense | -2,837 | -2,061 | -2,693 | -3,092 | -1,281 |
Interest & Investment Income | 610.42 | 1,506 | 1,130 | 1,087 | 130.36 |
Earnings From Equity Investments | - | 10,392 | 6,489 | -4,921 | -4,780 |
Currency Exchange Gain (Loss) | 580.94 | -2,570 | -651.41 | 329.73 | -149.04 |
Other Non Operating Income (Expenses) | 97.31 | 15,864 | -1,251 | 296.71 | -3,772 |
EBT Excluding Unusual Items | 31,696 | 58,989 | 33,886 | 20,789 | 18,565 |
Gain (Loss) on Sale of Investments | - | 46.49 | - | - | - |
Gain (Loss) on Sale of Assets | 49.79 | -9.2 | - | - | 1.71 |
Asset Writedown | - | - | -166.58 | -7.42 | -279.65 |
Other Unusual Items | - | - | -10.72 | - | - |
Pretax Income | 31,745 | 59,027 | 33,708 | 20,782 | 18,287 |
Income Tax Expense | 3,139 | 15,039 | 5,564 | 5,821 | 5,373 |
Net Income | 28,606 | 43,988 | 28,144 | 14,961 | 12,914 |
Net Income to Common | 28,606 | 43,988 | 28,144 | 14,961 | 12,914 |
Net Income Growth | -34.97% | 56.29% | 88.11% | 15.86% | -25.36% |
Shares Outstanding (Basic) | 15 | 15 | 15 | 15 | 16 |
Shares Outstanding (Diluted) | 15 | 15 | 15 | 15 | 16 |
Shares Change (YoY) | 0.03% | -0.01% | - | -0.61% | -1.61% |
EPS (Basic) | 1847.00 | 2841.00 | 1817.55 | 966.21 | 828.84 |
EPS (Diluted) | 1847.00 | 2841.00 | 1817.55 | 966.00 | 828.84 |
EPS Growth | -34.99% | 56.31% | 88.15% | 16.55% | -24.14% |
Free Cash Flow | 27,983 | 40,383 | 29,421 | 6,049 | 11,189 |
Free Cash Flow Per Share | 1806.77 | 2608.20 | 1900.03 | 390.67 | 718.13 |
Dividend Per Share | - | - | 500.000 | 500.000 | 500.000 |
Gross Margin | 28.02% | 25.83% | 25.31% | 25.38% | 28.87% |
Operating Margin | 12.89% | 16.12% | 14.92% | 14.34% | 16.73% |
Profit Margin | 11.09% | 19.77% | 13.61% | 7.92% | 7.60% |
Free Cash Flow Margin | 10.85% | 18.15% | 14.22% | 3.20% | 6.59% |
EBITDA | 51,437 | 51,595 | 46,393 | 42,045 | 41,661 |
EBITDA Margin | 19.95% | 23.19% | 22.43% | 22.25% | 24.53% |
D&A For EBITDA | 18,193 | 15,737 | 15,531 | 14,956 | 13,245 |
EBIT | 33,244 | 35,858 | 30,862 | 27,089 | 28,417 |
EBIT Margin | 12.89% | 16.12% | 14.92% | 14.34% | 16.73% |
Effective Tax Rate | 9.89% | 25.48% | 16.51% | 28.01% | 29.38% |
Advertising Expenses | 1,721 | 1,564 | 1,731 | 1,605 | 1,666 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.